文献速递贫血与红细胞疾病

羧基麦芽糖铁静脉输注与口服铁剂补充治疗结直肠癌患者术前缺铁性贫血(FIT):多中心、开放标签、随机对照试验

Ferric carboxymaltose infusion versus oral iron supplementation for preoperative iron deficiency anaemia in patients with colorectal cancer (FIT): a multicentre, open-label, randomised, controlled trial.
PubMed 文献 · Lancet Haematol · 2023-02-27

FIT多中心开放标签随机对照试验纳入202例M0期结直肠癌合并缺铁性贫血的择期手术患者,比较静脉羧基麦芽糖铁与口服富马酸亚铁。主要终点术前血红蛋白正常化比例两组无显著差异,但静脉铁组在术后30天时血红蛋白正常化比例显著更高,且铁储备恢复仅见于静脉铁组。

要点

  • 静脉铁组与口服铁组术前血红蛋白正常化比例分别为17%与16%,无显著差异。
  • 术后30天静脉铁组血红蛋白正常化比例60%,显著高于口服铁组21%。
  • 两组均未观察到治疗相关严重不良事件或死亡。

核心结论

  • 两种方案术前血红蛋白正常化均不常见,但静脉铁治疗后其他所有时间点血红蛋白正常化显著改善。
  • 铁储备恢复仅通过静脉铁治疗可行。
  • 作者认为,在选定患者中可考虑延迟手术以增强静脉铁对血红蛋白正常化的效果。

研究设计与样本

  • FIT为多中心、开放标签、随机对照试验,纳入年龄18岁及以上、M0期结直肠癌拟行择期根治性切除术、合并缺铁性贫血的成人患者。
  • 缺铁性贫血定义为女性血红蛋白低于7.5 mmol/L(12 g/dL)、男性低于8 mmol/L(13 g/dL),且转铁蛋白饱和度低于20%。
  • 患者随机分配至静脉羧基麦芽糖铁1-2 g组或口服富马酸亚铁每日三片200 mg组。
  • 主要终点为术前血红蛋白正常化比例(女性≥12 g/dL,男性≥13 g/dL),主要分析采用意向性治疗分析,安全性分析纳入所有接受治疗的患者。
  • 2014年10月31日至2021年2月23日共纳入202例患者,静脉铁组96例,口服铁组106例。

主要发现

  • 静脉铁组治疗开始至手术中位时间14天(IQR 11-22),口服铁组19天(IQR 13-27)。
  • 入院当日血红蛋白正常化:静脉铁组14/84例(17%),口服铁组15/97例(16%),相对风险(RR)1.08(95% CI 0.55-2.10),p=0.83。
  • 30天时血红蛋白正常化比例静脉铁组显著升高:静脉铁组49/82例(60%) vs 口服铁组18/88例(21%),RR 2.92(95% CI 1.87-4.58),p<0.0001。
  • 口服铁组最常见的治疗相关不良事件为粪便变色(1级),14/105例(13%);两组均未观察到治疗相关严重不良事件或死亡。
  • 最常见的严重不良事件为吻合口漏11/202例(5%)、吸入性肺炎5/202例(2%)和腹腔内脓肿5/202例(2%)。

临床怎么用

  • 作者认为,在选定患者中可考虑延迟手术以增强静脉铁对血红蛋白正常化的效果。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A third of patients with colorectal cancer who are eligible for surgery in high-income countries have concomitant anaemia associated with adverse outcomes. We aimed to compare the efficacy of preoperative intravenous and oral iron supplementation in patients with colorectal cancer and iron deficiency anaemia. METHODS: In the FIT multicentre, open-label, randomised, controlled trial, adult patients (aged 18 years or older) with M0 stage colorectal cancer scheduled for elective curative resection and iron deficiency anaemia (defined as haemoglobin level of less than 7·5 mmol/L (12 g/dL) for women and less than 8 mmol/L (13 g/dL) for men, and a transferrin saturation of less than 20%) were randomly assigned to either 1-2 g of ferric carboxymaltose intravenously or three tablets of 200 mg of oral ferrous fumarate daily. The primary endpoint was the proportion of patients with normalised haemoglobin levels before surgery (≥12 g/dL for women and ≥13 g/dL for men). An intention-to-treat analysis was done for the primary analysis. Safety was analysed in all patients who received treatment. The trial was registered at ClincalTrials.gov, NCT02243735, and has completed recruitment. FINDINGS: Between Oct 31, 2014, and Feb 23, 2021, 202 patients were included and assigned to intravenous (n=96) or oral (n=106) iron treatment. Treatment began a median of 14 days (IQR 11-22) before surgery for intravenous iron and 19 days (IQR 13-27) for oral iron. Normalisation of haemoglobin at day of admission was reached in 14 (17%) of 84 patients treated intravenously and 15 (16%) of 97 patients treated orally (relative risk [RR] 1·08 [95% CI 0·55-2·10]; p=0·83), but the proportion of patients with normalised haemoglobin significantly increased for the intravenous treatment group at later timepoints (49 [60%] of 82 vs 18 [21%] of 88 at 30 days; RR 2·92 [95% CI 1·87-4·58]; p<0·0001). The most prevalent treatment-related adverse event was discoloured faeces (grade 1) after oral iron treatment (14 [13%] of 105), and no treatment-related serious adverse events or deaths were observed in either group. No differences in other safety outcomes were seen, and the most common serious adverse events were anastomotic leakage (11 [5%] of 202), aspiration pneumonia (5 [2%] of 202), and intra-abdominal abscess (5 [2%] 202). INTERPRETATION: Normalisation of haemoglobin before surgery was infrequent with both treatment regimens, but significantly improved at all other timepoints following intravenous iron treatment. Restoration of iron stores was feasible only with intravenous iron. In selected patients, surgery might be delayed to augment the effect of intravenous iron on haemoglobin normalisation. FUNDING: Vifor Pharma.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Talboom K, Borstlap WAA, Roodbeen SX, et al. Ferric carboxymaltose infusion versus oral iron supplementation for preoperative iron deficiency anaemia in patients with colorectal cancer (FIT): a multicentre, open-label, randomised, controlled trial. Lancet Haematol. 2023. PMID: 36863386. doi:10.1016/S2352-3026(22)00402-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。